AMAG reports third quarter total revenues of $17.6 million AMAG Pharmaceuticals, Inc. today reported unaudited consolidated economic results for the third quarter ended September 30, 2011 revia 50 mg . Additionally, AMAG announced leadership changes, like the departure of the business’s president and ceo, Brian J.G. Pereira, MD, and the implementation of a wide restructuring plan to reduce operating expenditures. As of September 30, 2011, the company’s cash, cash equivalents and investments totaled around $251 million. Pereira provides resigned from his position as president, CEO and a director of the ongoing company, effective immediately.
Drug and Food Administration in the next half of 2012. AMAG’s partner, Takeda Pharmaceutical Company, is in charge of all regulatory filings looking for the broad IDA indication for Feraheme in its licensed territories.. AMAG completes enrollment in Feraheme Stage III program for iron-deficiency anemia AMAG Pharmaceuticals, Inc. Both research have completed enrollment now, with an increase of than 1,400 sufferers enrolled through 210 research sites globally. Allen, M.D., Ph.D., executive vice president and chief medical officer of AMAG. As we comprehensive data collection and evaluation over the next few months, the total results of the studies will form the basis for global regulatory submissions, which will seek to broaden the indication of Feraheme for the treating IDA beyond the current indication for adult individuals with chronic kidney disease.